phorbolol myristate acetate has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harada, T; Itamochi, H; Kawaguchi, W; Kigawa, J; Kudoh, A; Naniwa, J; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N; Uegaki, K | 1 |
1 other study(ies) available for phorbolol myristate acetate and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Chromones; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavonoids; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Morpholines; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; S Phase; Tetradecanoylphorbol Acetate; Xenograft Model Antitumor Assays | 2012 |